Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

3(33.3%)

Phase 3

2(22.2%)

9Total

Phase 1(4)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05163808Phase 2Completed

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Role: lead

NCT05367960Phase 3Active Not Recruiting

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Role: lead

NCT05358886Phase 3Completed

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

Role: lead

NCT03817684Phase 2Completed

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

Role: lead

NCT03569631Phase 2Completed

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

Role: lead

NCT04044781Phase 1Withdrawn

A Phase 1, Open-Label, PET Study of T2310 & BPN14770

Role: lead

NCT03030105Phase 1Completed

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Role: lead

NCT02648672Phase 1Completed

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

Role: lead

NCT02840279Phase 1Completed

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

Role: lead

All 9 trials loaded